Form 4: BioCryst Pharmaceuticals Director Receives Stock Grant

Director Frank Steven of BioCryst Pharmaceuticals received a grant of restricted stock units and stock options as part of the company's non-employee director compensation policy.

Summary

• Director Frank Steven was granted 15,294 shares of common stock on June 11, 2026, under the BioCryst Pharmaceuticals, Inc. Non-Employee Director Compensation Policy.
• Additionally, Steven received a grant of 33,540 stock options with an exercise price of $8.50, also under the Director Compensation Policy.
• The restricted stock units are set to vest on the first anniversary of the grant date.
• The stock options have an exercisable date of June 11, 2027, and an expiration date of June 11, 2036.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it represents routine director compensation rather than significant operational or financial news.

Positives

• Director compensation through equity awards aligns the interests of the director with those of shareholders.
• The grant of stock options with an exercise price of $8.50 suggests a belief in future stock price appreciation.
• Vesting periods for restricted stock units encourage long-term commitment from directors.

Risks

• The value of the granted stock options is subject to market fluctuations and the company's future stock performance.
• If the stock price does not exceed the exercise price of $8.50, the stock options may not be exercised profitably.

Future Outlook

The grant of stock options with an exercise price of $8.50 and a future vesting date implies a positive outlook on the company's future stock performance, though no specific financial projections are provided in this filing.

Industry Context

StockSavvy.ai notes that equity grants to directors are a standard practice in the biopharmaceutical industry to attract and retain experienced leadership and align their incentives with shareholder value creation.

Stakeholder Impact

• Shareholders: The equity grants align director interests with shareholder value, potentially leading to decisions that benefit the company's stock price.
• Directors: Receives compensation in the form of equity, providing potential for future financial gain tied to company performance.

Next Steps

• Restricted stock units will vest on the first anniversary of the grant date.
• Stock options will become exercisable on June 11, 2027.

Key Dates

Keywords

BioCryst Pharmaceuticals, BCRX, Form 4, Director Compensation, Stock Options, Restricted Stock Units, Insider Trading, Equity Grant